الرئيسية
استكشاف
nav.journalClub
الرائج
المزيد
synapse
⌘+K
اللغة
العربية
العربية
Impact of Infusion Timing on Safety and Efficacy of Anti-CD19 and Anti-BCMA CAR T Therapies | Synapse
March 3, 2026
Impact of Infusion Timing on Safety and Efficacy of Anti-CD19 and Anti-BCMA CAR T Therapies
SI
Sidharth Iyer
TV
Timothy Voorhees
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
ND
Nathan Denlinger
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
See all
Key Points
Infusion timing significantly impacts the efficacy of CAR T therapies, enhancing patient outcomes.
The analysis observed a notable increase in efficacy rates with optimal infusion timing during treatment.
This observational analysis evaluated the timing of anti-CD19 and anti-BCMA CAR T therapies.
Findings highlight the importance of infusion timing in optimizing clinical outcomes.
Mark Helpful
Like
Save
Bookmark
Relay
Share
Cite This Study
Copy
Iyer et al. (Sun,) studied this question.
synapsesocial.com/papers/69a76073c6e9836116a2d355
https://doi.org/https://doi.org/10.1016/j.jtct.2025.12.250
Mark Helpful
Like
Save
Bookmark
Relay
Share